Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hypophosphatasia: later-stage trial registry
3 of 7 indexed Hypophosphatasia trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 3 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Hypophosphatasia: 7 US clinical trials tracked, 3 recruiting.
Hypophosphatasia is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Alexion Pharmaceuticals, running 5 of these trials.
Enrollment posture brief
Registry condition hypophosphatasia
OPEN 3 | RECR 43% | LATE 3 | EARLY 1 | RANK #2497 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Adrenoleukodystrophy (43% recruiting · 7 trials)
Hypophosphatasia lists 3 open slots (43% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hypophosphatasia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hypophosphatasia is recruiting below its size-band peers.
3 of 7 indexed trials (42.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Hypophosphatasia research.
Alexion Pharmaceuticals accounts for 5 of 7 trials (71.4%). 3 distinct sponsors appear on at least one study for this condition label.
-
Most Hypophosphatasia trials plan to enrol fewer than 100 people.
Median target enrolment is 43 among the 7 trials that report a genuine target (sentinel values excluded). 5 of those (71.4%) plan for fewer than 100 participants.
-
Hypophosphatasia splits between interventional and observational designs.
4 interventional and 3 observational studies make up this index (57.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
Natural History Study of Patients With Hypophosphatasia (HPP)
Duke University
NCT02237625
United States Hypophosphatasia Molecular Research Center
Children's Mercy Hospital Kansas City
NCT05062629
A Prospective Sub-Study of the Global Hypophosphatasia Registry
Alexion Pharmaceuticals
NCT05234567
Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
Alexion Pharmaceuticals
NCT06079281
Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa
Alexion Pharmaceuticals
NCT06079372
Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP
Alexion Pharmaceuticals
NCT06079359
Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)
Alexion Pharmaceuticals
NCT01205152
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Hypophosphatasia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hypophosphatasia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hypophosphatasia page
7 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Hypophosphatasia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Alexion Pharmaceuticals sponsors the most Hypophosphatasia trials on record, review their full trial history before evaluating a specific study. See Alexion Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hypophosphatasia condition card totals 7 registered trials; most-linked intervention ALXN1850; top US site state Missouri. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.